Observational, longitudinal, prospective, prospective, comparative study of the effectiveness of triptans before and after onabotulintoxin A initiation in a single group of chronic migraine patients.

Hypothesis In patients with chronic migraine the efficacy of triptans, previously taken by the patient for the migraine attack, is better and more satisfactory after starting treatment with onabotulinumtoxinA.

Objectives To analyze the efficacy and satisfaction of the triptan usually taken by the patient with chronic migraine before starting preventive treatment with onabotulinumtoxinA, at 4 months, after two sessions of Botox, and at 7 months of treatment, after three sessions of Botox.

Sample size n=100 patients with chronic migraine in whom treatment with onabotulinumtoxinA is indicated. The indication for Botox treatment will be performed as usual and the patient will take his usual triptan if he has a migraine attack, so there is no therapeutic modification in this study that could involve any bioethical issue.

All patients signed the informed consent and the study was approved by the Comitè d'Ètica de la Investigació amb Medicaments (CEIm) de l'Hospital de la Santa Creu i Sant Pau.

Inclusion Criteria:

• ICHD-3 criteria for chronic migraine (code 1.3). See Table 3.
• Older than 18 years and younger than 65 years.
• Migraine started in their lifetime before the age of 50 years.
• Migraine of more than one year of evolution since diagnosis.
• Normal cranial CT/MRI study.
• Indication for treatment with Botox
• Taking triptans as a rescue treatment for migraine attacks

Exclusion Criteria:

• Pregnant women
• Migraine of less than one year of evolution since diagnosis.
• Pathologies that contraindicate the use of OnabotulinumtoxinA (myasthenia gravis, myopathies).

Patients who meet criteria for chronic migraine and have failed 2 or more oral preventive treatments (including topiramate) or have a contraindication to taking topiramate.